1. Christine’s legacy
Christine’s story (www.investinme.org/mestory0041.htm)
highlights how the NHS fails patients with hypopituitarism.
She describes how she was given the short synacthen test in
2006, and when she had a normal cortisol result despite her
condition worsening, was told that she did not have
pituitary disease. Instead, she was misdiagnosed with
Chronic Fatigue Syndrome, and it was only much later, thanks
to Professor Hooper’s help, that she was correctly diagnosed
with hypopituitarism and at long last received the hormone
treatment she needed.
My name is Jill and I too was incorrectly
diagnosed with CFS on the basis of the short synacthen test
administered by the same endocrinologist. I read an article
by Christine in a newsletter from the support group Thyroid
UK
www.thyroiduk.org
and got in touch. We became friends and worked together to
highlight the shortcomings of the test, and to urge
professionals to address the difficulties of testing for
cortisol deficiency when it is caused by pituitary
dysfunction.
Eventually, we found an endocrine team who
were prepared to conduct further investigations. The
glucagon stimulation test [1], revealed deficiencies
in both growth hormone and cortisol, a steroid hormone
essential for life. Our diagnosis was changed from CFS to
pituitary dysfunction caused by autoimmune disease.
It is with great sadness that I write of
Christine’s untimely death. Since mid-2010, when her
bladder stopped functioning, she had been wearing a
catheter. She battled bravely with the problem, her stamina
and determination were always a wonder to behold, but in
March 2011 she received a bitter blow. She had been pinning
all her hopes on a leaflet which the Society for
Endocrinology (SfE) were producing, which she thought would
clarify once and for all which tests should be used for
diagnosing low cortisol in adrenal insufficiency from
whatever cause. When the leaflet came out it was an utter
disappointment. This was when her bowel burst and she lost
all hope. It was devastating to see. She discharged herself
from hospital and there can only be praise for her husband
whose devoted care continued until her death in July 2011.
Her final wish was that the battle she
started would save people from being left to suffer because
of the inadequacies of the short synacthen test to identify
cortisol deficiency in pituitary dysfunction. I think she
would also wish to broadcast as widely as possible the
events that led up to the publication of the SfE leaflet –
events, which deeply shook our faith in the NHS complaints
system.
2. The NHS complaints procedure
In 2007 we each made a complaint about the endocrinologist.
The Chief Executive of the hospital did not uphold our
complaints. In Christine’s case he wrote, “This is a
definitive test used for investigating adrenal failure and
these results excluded the possibility of a pituitary
abnormality causing your adrenal insufficiency.” In my case
he wrote “There was no evidence clinically or biochemically
to support pituitary dysfunction.”
We then made separate NHS complaints to the
Healthcare Commission (HCC), which again were not upheld.
In Christine’s case they obtained medical
advice from a Consultant Endocrinologist. He stated, “That
the short synacthen test, which is used for Addison’s
disease, is the standard test for adrenal insufficiency
widely known by trained endocrinologists in the UK would, to
the best of his knowledge, not agree that your test was
unequivocally normal.”
The independent endocrinologist for my own
complaint wrote, more guardedly, that a Short Synacthen test
was often used as a first-line conventional test of
adrenocortical function.
In April 2009 we made a joint complaint to
the Parliamentary and Health Service Ombudsman (PHSO) that a
‘normal’ result from the short synacthen test did not rule
out cortisol deficiency caused by pituitary disease. Our
evidence proved that the endocrinologists’ statements to the
HCC had been incorrect. We wrote that we were particularly
concerned because we thought the first medical witness could
have been a clinical expert and patient advocate, selected
by the professional/specialist and patient/care groups [2].
We were hopeful that because the PHSO was promoted in their
“Principles” document as an independent, customer-focused,
open and accountable body, we would receive fair treatment.
However, in September 2009 the PHSO reported
that they could not find an endocrinologist who would
comment, and in October, after taking six months rather than
the normal six weeks, they did not uphold our complaints.
Their response did not even mention the word “pituitary”. In
contrast to the HCC they did not provide the name or medical
qualifications of the Professional Adviser they had used.
The Independent Complaints Advocacy Service
(ICAS) wrote that if the PHSO hadn’t missed or
misinterpreted any aspect of our complaint we had reached
the end of the NHS procedure.
We had followed the complaints procedure for
over three years and were disillusioned not to obtain
justice. We could have applied for a Judicial Review but
rejected the idea because we were uncertain where the
responsibility lay and an earlier Judicial Review had been
unsuccessful [3]
We wrote to ICAS and the PHSO, including the
Ombudsman, Ann Abraham, pointing out that significant
information in our complaints had been missed and
misinterpreted. We also wrote to Andy Burnham at the Dept of
Health, all members of the Houses of Lords and Commons, the
Strategic Health Authorities (SHAs) and Patient Safety
Groups.
We asked the PHSO in November 2009 under the
Freedom of Information Act for full details of their
Professional Adviser. They did not respond within the
statutory 40 days, and when they finally did in February
2010, it was to provide the adviser’s qualifications – MD,
FRCP (Retired Consultant Physician & Endocrinologist) – but
not his name. Their excuse was “in considering whether to
disclose the information the public interest test was
applied, the interest can be met without disclosing the name
of the adviser, which would cause an unwarranted invasion of
their privacy.”
Our reaction was that the PHSO should have
treated as suspect, advice from someone who did not support
the customer and wished to remain anonymous. A person paid
by a public body to give clinical advice should not be
entitled to privacy. However the PHSO wrote they would
challenge as premature any application to the court before
their internal review procedure was completed.
We were also concerned that a retired health
professional would not have up-to-date knowledge and would
be likely to have the “fixed attitude about causation” which
a recent report had pinpointed among health professionals
treating ME [4].
The PHSO asked for a recent acknowledgement
by the SfE of the failure of the 250-mcg Synacthen test and
of the SHAs’ failure to provide facilities for pituitary
disease, which we duly supplied.
In April 2010 the SfE Clinical Committee
Chair wrote to me that they would be providing information
that would describe reliable ways of measuring a person’s
cortisol level (including information on the synacthen test)
and that would clarify the relationship between cortisol
deficiency and endocrine disorders. We were further
encouraged by a letter to Christine in January 2011 from the
SfE Public and Media Relations Office, agreeing with her
that if a patient received the short synacthen test and
the results came back as in the normal range, but the
patient still exhibited clinical symptoms characteristic of
adrenal insufficiency, then further testing to rule out
hypopituitarism should be arranged for the patient.
Christine and I were jubilant, believing that our battle had
been won. She immediately wrote to the Chief Executive of
the hospital - which had failed to carry out further
testing.
However, in March 2011, the long awaited
leaflet from the SfE was published and all our hopes
collapsed. It did nothing to resolve the problem of testing
for cortisol in pituitary disease. Despite everything, it
implied that the synacthen test was a suitable tool for
diagnosing pituitary disease. We were totally frustrated by
the NHS complaints procedure. No one would tell us we were
wrong, but nothing was being done.
By the time Christine received a reply from
the Chief Executive, which confirmed that their practice was
now in line with NICE Technology Appraisal 64, she was too
ill to query why the PHSO had not advised her of the
changes, or why the SfE’s leaflet was inconsistent with
their statement in January.
Four months after the
publication of the leaflet, she died.
Meanwhile, I made
protests about the leaflet to the PHSO, DoH, SHAs and the
SfE.
Early in July 2011, the longstanding
principle that an expert witness was immune from being sued
was overturned [5]. Hopefully, this will ensure in future
medical advisers respond truthfully, rather than protecting
their colleagues from legal action for negligence and
misdiagnosis.
In August the SfE wrote they would be happy
to help the PHSO. The SHAs were still concerned about the
failure of endocrine testing and NHS service provision for
ME/CFS/Pituitary patients and recommended I remain in
dialogue with the SfE. Despite advising the PHSO and
Christine’s husband writing to his MP, neither he nor I have
been told that lessons have been learned from our
complaints.
"It is only if health professionals
are willing to open their minds to widen their
knowledge when faced with patients with problems as
complex as ours that they will be able to arrange
correct referrals and investigations."
3. Education
We have to take responsibility for our
health. Christine’s
and my experience prove that by educating yourself and
others, admittedly not easy when you are not well, you can
receive help. Remember there are advances in the medical
world all the time; it is not always that our symptoms are
ignored for financial reasons.
We are dependent on health professionals to
help us solve our problems. No matter how frustrated you
get, act in a reasonable manner, remember we are all human
and none of us respond well to aggression. Also it is
negative to think all health professionals are deliberately
obstructive.
The problem is more that medicine is becoming
“evidence based”, which can stop health professionals using
their clinical expertise of patients’ signs and symptoms
when making a referral/diagnosis because the patient has
“normal” test results. But it should be remembered that
health professionals do have a legal and contractual duty to
act in the best interests of the patient.
When you have unresolved health problems
there should be meaningful repeat investigations. It may be
we have to accept that the answer to our problems cannot be
found, but the health professional must explain why. For a
patient it is of utmost importance for health professionals
to show a caring attitude and give hope.
My case is unique in my hospital’s endocrine
department and GP Practice and has taken from 1987 to be
diagnosed correctly. My experience leads me to believe that
some diseases are only considered rare because the
medical profession does not know enough about them. It is
only if health professionals are willing to open their minds
to widen their knowledge when faced with patients with
problems as complex as ours that they will be able to
arrange correct referrals and investigations.
4. A message of hope
There is hope, the Department of Health (DoH)
wrote in March 2010 that the government recognised CFS/ME as
a debilitating and distressing condition. It was a chronic
illness and health and social care professionals should
manage it as such.
In December 2010, in response to a letter
sent to Andrew Lansley, the DoH agreed with the WHO
classification of CFS/ME as a neurological condition of
unknown cause with many different potential causal factors,
including those of a neurological, endocrinal,
immunological, genetic, psychiatric, and infectious nature.
In the November 2012 issue of the ME
Association (MEA) Essentials magazine, there was a
misleading article about the synacthen test. The MEA
www.meassociation.org.uk
agreed that they would print my response letter sent in the
February issue of the magazine. If your symptoms are
indicative of pituitary dysfunction and the endocrinologist
will only conduct the synacthen test, please show him the
explanation why further testing needs to be done to rule out
a cortisol deficiency. [6]
With such complex causal factors, each of our
journeys will be different. From my experience, it is
difficult to imagine there is an easy cure for
such chronic illness, but once your problems are
acknowledged you will receive help and hopefully it will not
be too late for you to lead a good life.
5. Help promote Christine’s Legacy
Information has still not been provided on
reliable ways of testing for cortisol deficiency (including
information on the synacthen test), which is so vital to
clarify the relationship between cortisol deficiency and
endocrine disorders. However, in recent weeks the DoH has
written that NICE has been asked to develop a clinical
guideline and quality standards on adrenal dysfunction
http://www.nice.org.uk/guidance/cg/indevelopment/GuidelineReferralsUnderpinStandards.isp.
The Countess of Mar has been regularly
updated on Christine’s and my endeavours, and she considers
the problem will only be resolved from the
“bottom
up”.
It is up to us to discover which are the most
suitable tests and to share the relevant research with
endocrinologists. This will ultimately mean that NICE
provides a useful guideline on adrenal dysfunction and
revises NICE guideline 53 appropriately.
I hope the good news that I am at last receiving help that I
should have received in 1987, which has improved my health
considerably, makes you realise that we have to restore our
faith in mainstream medicine and the NHS.
Minds must be opened, so if you are having
difficulties obtaining help, educate yourself, write to your
health professional with full details of your medical
problems. This helps both you and them assess the situation
and if you are unable to obtain help, the papers will be
useful if you need to make an NHS complaint or legal claim.
Christine and I, were a great help to each
other, we could not have made this journey on our own. It
was sad to see her lose hope because of establishment
failure.
Hopefully, publicising her story will ensure
her final wish to stop the suffering of patients with
pituitary dysfunction will come one step closer.

References:
1 |
NICE Technology Appraisal 64 - Human
growth hormone (somatropin) in adults with growth hormone
deficiency, para 2.5 states, “The ITT is regarded as the
‘gold standard’ test.” When the ITT is contraindicated other
tests - such as response to GH-releasing hormone, arginine
or glucagon can be used.” |
2 |
Appendix B, para C of NICE Technology
Appraisal 64) |
3 |
Douglas Fraser 2) Kevin Short and NICE
about Clinical Guideline 53 Neutral Citation Number: (2009) EWHC Admin (452). Case No: CO/10408/2007 and CO/10435/2007
|
4 |
December 2009, Interim Report on the
Inquiry into NHS Service Provision for ME/CFS, by the All
Party Parliamentary Group (APPG) on ME – Recommendation 8
highlighted the difficulty of finding a suitably qualified
clinician to provide unbiased advice. It noted evidence that
there were serious concerns about acceptability, efficacy
and safety with some treatments and gave one reason as fixed
attitudes about causation among some health professionals. |
5 |
Supreme Court decision of Jones v Kaney – The Medical
Protection Society (MPS), Director of Policy and
Communication, Dr Stephanie Brown said,
“Having
lost their immunity, experts are now exposed to the risk of
evidence given in court”.
MPS indemnity extended to expert witness work and they would
be monitoring whether the ruling would open the floodgates
in terms of court proceedings. |
6 |
ME Essential
Magazine – Why further testing need to be done to rule out
cortisol deficiency
I would like to respond to Dr Shepherd’s
advice in the Autumn 2012 issue, on the use of the short
synacthen test (SST). The test is easy to administer and
increasingly popular; and is highly reliable for diagnosing
primary adrenal insufficiency (Addison’s disease) when the
problem lies in the adrenals themselves. However, it is
important to remember that it cannot be used to exclude
secondary adrenal insufficiency, caused by the pituitary
gland’s failure to stimulate the adrenal glands. You may
have a normal result to this test but still have pituitary
disease.
In 2011, the Society for Endocrinology (SfE)
wrote to the late Mrs Christine Wrightson (whose story can
be found on
www.investinme.org/mestory0041.htm as
follows:
“Our Clinical Committee … agree with your
analysis of the situation that if a patient receives the
short synacthen test and the results come back as in the
normal range, but the patient still exhibits clinical
symptoms of adrenal insufficiency, then further testing to
rule out hypopituitarism should be arranged for the
patient.”
A convenor of the SfE’s Special Interest
Group for Laboratory Aspects of Clinical Endocrinology
states:
“The Synacthen test does not test the whole
pituitary-adrenal axis”. [1]
A 2003 review covering 36 years of research
found that the synacthen test has only 57% - 61% sensitivity
for adrenal insufficiency caused by pituitary failure i.e.
misses two people in every 5. [2]
My own experience as well as Christine’s
supports this. In 2006 and 2010, I had the short synacthen
test with normal results. However, my symptoms persisted and
in 2012, the glucagon stimulation test confirmed adrenal
insufficiency due to pituitary disease. Cortisol was low and
I am now benefiting from the prescription of hydrocortisone.
[1]
click here
[2] Dorin RI et al, Diagnosis of adrenal insufficiency,
Annals of Internal Medicine 2003; 139: 194 –204. This review
“searched the Medline database for all research on the topic
between 1966 and 2002 and found that the sensitivity of the
250 microg (synacthen) test is 57% and the sensitivity of
the 1 microg test is 61%.
|

|